Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China

Summary

The purpose of this study is to monitor and evaluate the safety and effectiveness of Delamanid in combination with an optimal background regimen (OBR) of anti-TB drugs for treatment of MDR-TB.

Timeline

Start

2020-07-16

Primary completion

2022-06-16

Completion

2024-07-16

Publications

• Qin Y, Chen Y, Cai Q. Interim efficacy and safety analysis of the regimen containing delamanid in the treatment of multidrug resistant/rifampicin-resistant/extensively drug-resistant tuberculosis: a single-arm, prospective, monocentric, observational study. BMC Infect Dis. 2025 Dec 19;26(1):124. doi: 10.1186/s12879-025-11945-9.
• Yang F, Yin M, Jiang X, Zhao X, An X, Liu Y, Yuan Y. Delamanid-containing regimens over 24 weeks for the treatment of multidrug-resistant/rifampicin-resistant tuberculosis: preliminary results from a single center in a multicenter, prospective, observational study. Front Med (Lausanne). 2025 Sep 29;12:1631030. doi: 10.3389/fmed.2025.1631030. eCollection 2025.

Drugs

Indications